Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State

Authors: Hoenig, Michel R.; Kostner, Karam M.; Read, Stephen J.; Walker, Philip J.; Atherton, John J.

Source: Endocrine, Metabolic & Immune Disorders - Drug Targets(Formerly Current Dru, Volume 7, Number 3, September 2007 , pp. 153-166(14)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

The full text is free.

View now:

PDF 276.9kb

Abstract:

Obesity and the metabolic syndrome are becoming one of the biggest health challenges of the 21st century. Cholesterol metabolism is significantly altered in both obesity and metabolic syndrome in that cholesterol synthesis is increased and absorption reduced and this has important implications for the treatment of lipid disorders in both obesity and the metabolic syndrome. In the present review we discuss these changes in detail especially in the context of a more standardized approach for cholesterol reduction like the TARGET LDL trial. Customized care is topical in lipidology as we strive to achieve LDL cholesterol and non-HDL cholesterol targets in every patient.

Keywords: Cholesterol; cholestanol; statins; obesity; metabolic syndrome; diabetes; ezetimibe

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187153007781662567

Publication date: 2007-09-01

More about this publication?

This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.